Breakthrough infection in the two vaccine groups
infection, fever
INFECTION, CHRONIC DISEASES, INFLUENZA
Between 13 December 2022 and 16 January 2023, 66.49% (127/191) of participants developed symptoms and had positive nucleic acid or antigen test results, 9.95% (19/191) of participants developed symptoms and had suspected infection without nucleic acid or antigen test results, 1.57% (3/191) of participants were asymptomatic and had positive nucleic acid or antigen test results, and 21.99% (42/191) were asymptomatic with or without nucleic acid or antigen test results. The breakthrough infection peak occurred between 20 December 2022 and 26 December 2022 counted 47.12% (90/191) during this time (Epidemiologic curve of breakthrough cases. Daily numbers of confirmed cases, suspected cases, and asymptomatic cases. In March 2023, the participants were followed up by telephone to collect information on breakthrough infection. The breakthrough infection occurred from 13 December 2022 to 16 January 2023. Peak occurred between 20 December 2022 and 26 December 2022, counted 47.12% (90/191) during this time.Survival curves of breakthrough infection. The Cox model estimate shows the cumulative probability of breakthrough infection by vaccination type adjusted for sex, age, chronic diseases, and influenza vaccine history, starting on 12 December 2022.In total, 14.14% (27/191) of participants visited outpatient clinics for treatment and 50.26% (96/191) of participants significantly recovered from symptoms within 3 days. However, 1.05% (2/191) of participants (female, inactivated vaccine booster) had symptoms from which they had not significantly recovered more than 2 months after infection. No statistical differences were observed in the incidence of COVID-19 (The basic profile and symptoms of breakthrough infection.The “uninfectionBreakthrough symptoms of the two vaccine groups. The incidence of fever in the Ad5-nCoV group (54.74%) was lower than that in the inactivated vaccine group (71.88%, 